

Optical Coherence Tomography Image Analysis for Detection of Alzheimer's Disease: A Comprehensive Structured Review

Wan Mahani Hafizah Wan Mahmud^{1,*}, Audrey Huong Kah Ching¹, Nur Anida Jumadi¹, Raja Mohd Aizat Raja Izaham², Hong-Seng Gan³

² Kolej Kemahiran Tinggi MARA Ledang, Sungai Mati, 84410 Ledang, Johor, Malaysia

³ School of AI and Advanced Computing, XJTLU Entrepreneur College (Taicang), Xi'an Jiaotong-Liverpool University, Wuzhong District, Suzhou, Jiangsu, 215400 China

ABSTRACT

Optical Coherence Tomography (OCT) has emerged as a promising non-invasive imaging modality for the early detection of Alzheimer's Disease (AD). This systematic literature review aims to consolidate current research on OCT image analysis for AD detection, addressing the growing need for early and accurate diagnostic tools. Despite the advances in neuroimaging, early diagnosis of AD remains challenging due to its asymptomatic nature in initial stages and the invasiveness of traditional methods. To achieve this, we conducted an extensive search of related articles from reputable databases (Scopus and Web of Science), focusing on studies published between 2022-2024. The flow of study was based on PRISMA framework. The database found (n = 29) final primary data. This review was divided into three themes, (1) retinal and ocular biomarkers for AD, (2) optical coherence tomography angiography (OCTA) and imaging techniques, and (3) machine learning and computational approaches for Alzheimer's disease diagnosis. Key findings include the enlargement of the periarteriole capillaryfree zone and changes in retinal nerve fibre layer thickness as potential AD biomarkers. Based on the review, the implementation of image analysis for OCT images have shown substantial potential for AD detection. By evaluating the past studies, gaps for the current research were discovered including the need for larger, more diverse cohorts and longitudinal studies to validate these biomarkers. In summary, detection of AD is Keywords: possible through thorough OCT image analysis, but further research could be suggested Optical coherence tomography; Retina; to enhance its clinical applicability and reliability. Alzheimer's disease; Detection

1. Introduction

Millions of people across the globe are affected by Alzheimer's disease (AD), a degenerative mental illness and dementia's most common cause [1,2]. This implies that AD is a significant problem for individuals, families, and healthcare providers due to its progressive cognitive decline and

* Corresponding author.

https://doi.org/10.37934/araset.61.2.4157

¹ Department of Electronic Engineering, Faculty of Electrical and Electronics Engineering, Universiti Tun Hussein Onn Malaysia, 86400 Batu Pahat, Johor, Malaysia

E-mail address: wanmahani@uthm.edu.my

memory loss. In this light, amyloid-beta plaques as well as neurofibrillary tangles accumulate in the brain causing neuron death and atrophy of the brain, which are all part of Alzheimer's pathology. Early diagnosis is essential in managing and treating AD since it slows the progression of the condition leading to better outcomes. Though available diagnostic techniques such as clinical appraisal, neuropsychological tests, magnetic resonance imaging (MRI) neuroimaging along with positron emission tomography (PET) have some limitations regarding accessibility cost as well as invasiveness [3,4]. Consequently, more affordable, less invasive and accessible tools for diagnosis are needed urgently.

AD diagnostics have seen the rise of optical coherence tomography (OCT) as a promising imaging modality. OCT is an imaging technology that is non-invasive, and it can be used to capture high-resolution, cross-sectional images of living tissues through using low-coherence interferometry. OCT was originally developed for ophthalmology and specially for imaging the retina; however, its potential to detect AD related neurodegenerative changes has attracted much attention [5-7]. The retina being an extension CNS undergoes similar degeneration process just like that in brain. This, therefore, makes retinal imaging a useful parameter for studying and diagnosing neurodegenerative disorders like Alzheimer's disease (AD). There are several studies that have shown specific retinal biomarkers discernible by means of OCT which are associated with AD. These include thinning of RNFL, loss of ganglion cells and changes in overall retinal thickness. It has been proposed that these abnormalities in the retina could mirror the neuropathological modifications in brains characterizing the early stages of AD. Figure 1 shows mechanism of neuronal damage and Alzheimer's disease (AD) progression [3]. In addition to this concept, it has also been hypothesized about "retinal amyloidopathy" where amyloid-beta deposits central to AD pathology may accumulate within the eye's retina as well. These findings have spurred interest in using OCT as a diagnostic tool for AD.

The integration of advanced image analysis techniques, mainly those involving machine learning (ML) and deep learning (DL), has led to a great deal of improvement in the diagnostic potential for OCT. For example, OCT images can be analysed by machine learning algorithms like support vector machines (SVM) and convolutional neural networks (CNN) in order to detect subtle and complex patterns which are indicative of AD. These algorithms can process large datasets and extract features that cannot be easily seen by human observers thereby enhancing diagnostic accuracy and reliability [8-10]. Some studies have shown that ML and DL methods achieve high sensitivity and specificity for distinguishing patients with AD from healthy subjects based on OCT images alone [11-14]. However, there remain some issues that must be solved before OCT is fully embraced as a tool for diagnosing AD. Standardized methods are imperative so as to ensure uniformity across different OCT devices, imaging protocols, as well as patient populations. Furthermore, long-term studies need to be conducted so that the temporal relationship between retinal changes could establish with disease progression. Integrating OCT findings with other biomarkers, such as cerebrospinal fluid (CSF) biomarkers and genetic markers, could provide a more comprehensive understanding of AD pathology and enhance diagnostic precision.




Fig. 1. Mechanism of neuronal damage and Alzheimer's disease (AD) progression [3]

To sum up, optical coherence tomography is a very significant method for early diagnosis and monitoring of Alzheimer's disease. Besides being non-invasive, it can also identify differences in the retina that are related to AD implying a possible future usage as an extra diagnostic tool instead of traditional ones. It is foreseeable that utilization of machine learning and deep learning techniques improved by advancements in imaging technology will even increase the usefulness of OCT in the clinic. With more research ongoing, OCT may become an indispensable tool for diagnosing Alzheimer's, presenting new avenues for early intervention or better patient outcome.

2. Literature Review

Optical coherence tomography (OCT) has become a major instrument for the early detection and monitoring of AD. OCT imaging in the retina allows the in vivo, non-invasive observation of changes to the retinal microvascular and neural structures that may correlate with AD progression. Chen et al., [15], Popovic et al., [16] and Adejumo et al., [17] report that studies demonstrate that the developments in the retina, as shown by measures of microvascular complexity and WLR abnormalities, are the most prominent markers for neurodegenerative processes related to AD. These alterations become measurable even before the first clinical symptoms are manifested, thus placing OCT as a potential early diagnostic tool. Chen et al., [15] performed a meta-analysis associating the positive correlation in retinal thickness associated with hippocampal volume in patients with AD. The authors' systematic review revealed that retinal thinning in patients with AD is correlated with hippocampal atrophy, which is a hallmark of AD. This association might indicate that imaging of the retina could reflect the CNS component of AD changes, opening a window into the health of the brain through the eyes. This study complements the findings by Popovic et al., who pointed out retinal microvascular complexity as a potential marker of biological age and age-related diseases including AD. These data on reduced retinal microvascular complexity are based on quantification methods, in particular Sholl's and box-counting fractal analysis. Further reinforcing

these results, Adejumo *et al.*, [17] showed that OCT could measure the WLR in the retinal blood vessels, showing abnormalities in the mouse models of AD. In their research, they employed adaptive vessel tracing and segmentation methods to achieve this measurement with very high accuracy, hence further defining the potential use of OCT in the detection of early pathological changes within retinal structures. It suggests that microvascular changes at the retina may act as sensitive markers for the early detection of AD and follow-up. Further, Hui *et al.*, [18] used DRL in combination with OCT for automatic AD detection. While reviewing their study, it was realized that DRL would enhance the precision and efficiency of analysis in retinal imaging. It will therefore deploy state-of-the-art AI techniques to enhance diagnostic accuracy of OCT and help the technique find broader applications in the clinic. Empowerment using AI in retinal imaging would make it possible to diagnose the early stages of AD and subsequently monitor patients by identifying those at high risk and monitoring disease progression non-invasively.

The quest for retinal imaging biomarkers is further enriched by work from Batista et al., [19], where changes in retinal thickness in animal models with AD were investigated. These studies detected changes at the early stages of illness, which showed important retinal changes; as such, these biomarkers would have been detected many years prior to the clinical beginning of the disease—very basic for timely intervention and thus better patient outcomes. This study has also demonstrated the feasibility of optical coherence elastography in association with OCT for in situ measurements of retinal elasticity, hence providing access to additional layers of diagnostic information. On a clinical scale, Cordeiro et al., [20] have designed Detection of Apoptosing Retinal Cells technology using Annexin A5 fluorescently labelled to highlight stressed and apoptotic cells in the retina. This technology, according to them, proved through research that DARC, in association with AI algorithms, is capable of actually making some disease activity predictions related to glaucoma and AMD patients. An extension of this technology to AD will have provided another noninvasive biomarker for early detection and follow-up in the disease. The research body underlines the role of OCT in detecting AD-related changes within the retina. Studies have been very strong to the effect that retinal imaging discloses an AD-associated microvascular and structural alteration. It, therefore, becomes a very useful non-invasive tool in early diagnosis and monitoring. Advanced imaging integrated with AI enlarges the diagnostic possibilities of OCT and holds significant potential for improvement in the management of AD.

This has been the case with optical coherence tomography image analysis in Alzheimer's Disease detection, where it has huge potential as a non-invasive diagnostic tool. Actually, several studies have used the advanced imaging techniques to study changes in the retina associated with AD, delineating a possible role for OCT in the early detection and follow-up of AD. Nahid Sami et al., [21] have pointed out the role of deep learning algorithms combined with OCT and OCT angiography techniques for identifying early-stage AD biomarkers. Their detailed analysis explained how such technologies might provide a better prediction for AD by capturing local and global retinal features, which are very important for therapy and treatment planning. The avenue for early intervention in the process of AD may be a combination of both: non-invasive imaging and sophisticated computer algorithms. Jianyang Xie et al., [22] focus on the application of Optical Coherence Tomography Angiography (OCTA) to investigate changes in the retinal microvasculature in the process of AD and amnestic mild cognitive impairment. Their study showed that vessel area and length densities were significantly reduced, especially at inner vascular complexes of AD patients compared to HC. These vascular changes, reflecting the advancement of AD and MCI, further support OCTA as a very useful diagnostic tool. Their framework, with a deep learning model-based standardized analysis, provides a robust way for further clinical applications and research. T. Prasath and V. Sumathi [23] presented a review of various techniques with a base of imaging in AD detection, placing an emphasis on the shift from

brain imaging to retinal imaging. The scientists said in the review that non-invasive approaches, like OCT and digital retinal photography, easily identify biomarkers associated with neurodegeneration; thus, offering quite a feasible solution for the diagnosis of early AD. In that respect, the thickness of the RNFL layer is related to the seriousness of AD. This goes on to mean that, especially in the case of OCT imaging, this technology might be an effective process of screening within a clinical context.

Carol Y. Cheung *et al.*, [24] have gone a step further to explain the relationship that exists between the change in the retina and cognitive impairment. From their findings, it has been shown that the OCT quantitative measurements were significantly associated with AD, relating to the thinning of various retinal layers and reduced capillary density. Computer algorithms in the analysis of retinal images have been developed, which further enhances the potential of OCT as a quick screening tool and facilitates early detection and monitoring of AD progression. Figure 2 shows imaging of retinal capillary network using optical coherence tomography angiography (OCTA), which is not visualised using conventional retinal camera [24]. Lastly, Susanne Jentsch *et al.*, [25] used fluorescence lifetime imaging ophthalmoscopy for the detection of retinal changes in patients suffering from AD. Their pilot study revealed that FLIO parameters were significantly correlated to non-ocular markers specific to AD, including the MMSE score and cerebrospinal fluid concentrations of amyloid- β and tau proteins. In contrast to conventional OCT, FLIO was able to deliver further details about the retinal changes related to AD, thus supporting the possibility that combinations of different imaging methods might improve diagnostic accuracy.




Fig. 2. Imaging of retinal capillary network using optical coherence tomography angiography (OCTA) [24]

Overall, advances in OCT and related imaging technologies have contributed enormously to the early detection and monitoring of Alzheimer's disease. Researchers could further enhance diagnostic capabilities brought in by these non-invasive techniques with deep learning algorithms, only after developing appropriate innovative analysis frameworks. It is such potential of OCT and OCTA techniques, integrated into clinical practice, which is going to accomplish timely and accurate diagnosis of AD, very necessary for its effective treatment and management.

3. Material and Methods

3.1 Identification

Several key steps in the systematic review process were used to choose a great deal of relevant literature for this study. First, keywords are selected, and then related terms are searched for using

dictionaries, thesaurus, encyclopaedias, and past research. All relevant keywords were selected once the search strings for the WoS and Scopus databases were created (see Table 1). During the first stage of the systematic review process, 448 publications were successfully retrieved for the current study project from both databases.

Table 1

The searc	h string
Database	Search String
Scopus	TITLE-ABS-KEY (("Optical Coherence Tomography" OR oct) AND detect* AND alzheimer*) AND (LIMIT- TO (PUBYEAR , 2022) OR LIMIT-TO (PUBYEAR , 2023) OR LIMIT-TO (PUBYEAR , 2024)) AND (LIMIT-TO (LANGUAGE , "English")) AND (LIMIT-TO (PUBSTAGE , "final")) AND (LIMIT-TO (SRCTYPE , "j") OR LIMIT-TO (SRCTYPE , "p")) AND (LIMIT-TO (DOCTYPE , "cp") OR LIMIT-TO (DOCTYPE , "ar"))
	Access Date: May 2024
WoS	("Optical Coherence Tomography" OR oct) AND detect* AND alzheimer* (Topic) and Article or Proceeding Paper (Document Types) and English (Languages) and 2021 or 2022 or 2023 or 2024 (Publication Years) and 2024 or 2023 or 2022 (Publication Years)
	Access Date: May 2024

3.2 Screening

Researchers created inclusion and exclusion criteria, which were used to screen 448 papers during the first phase (see Table 2). The literature in the form of research articles and conference proceedings was the main selection criterion because it offers useful information. As a result, publications such as books, book chapters, meta-analyses, reviews, systematic reviews, and reviews were excluded from the study. Furthermore, only English-language papers were included in the review. It is imperative to emphasize that the study was conducted over a three-year period (2022–2024). A total of 353 publications were disqualified according to a particular criterion. Twenty materials that were duplicates in both databases were also eliminated in the second round.

Table 2									
The selection criterion in searching									
Criterion	Inclusion	Exclusion							
Language	English	Non-English							
Timeline	2022 – 2024	< 2022							
Literature type	Journal (Article) and proceeding	Book, Review							
Publication Stage	Final	In Press							

3.3 Eligibility

The third stage was the eligibility assessment, whereby seventy-five articles were aggregated. This involved an in-depth analysis of each article's title and texts to ascertain whether the papers fitted within the set inclusion criteria and were relevant to the study aim being undertaken. 46 datasets, papers and articles were therefore determined as ineligible for inclusion. Excluded in the process were: those that were irrelevant to the reason for the study, their abstracts turning out to be of no relevance to the investigation at hand, those outside this field, and articles with no full-text accessibility supported by empirical data. This has therefore reduced it to 29 papers to be reviewed in the future.

3.4 Data Abstraction and Analysis

This section discusses the results obtained from the surface pressure measurement study. The effects of angle of attack, Reynolds number and leading-edge bluntness are discussed in the next sub section. In this study, an integrative analysis was employed as one of the assessment strategies to examine and synthesize a range of research designs, specifically focusing on quantitative methods. The primary aim of the study was to identify relevant topics and subtopics. The initial step in theme development was the data collection stage. As depicted in Figure 3, the authors meticulously analysed a compilation of 29 publications for assertions or material pertinent to the study's topics. Subsequently, they evaluated significant studies related to optical coherence tomography image analysis for Alzheimer's disease detection. The methodologies and research results of these studies were thoroughly investigated. The author, along with co-authors, collaborated to develop themes based on the evidence within the context of this study. A log was maintained throughout the data analysis process to record any analyses, viewpoints, puzzles, or other thoughts relevant to data interpretation. Finally, the authors compared the results to identify any inconsistencies in the theme design process. In cases of conceptual disagreements, the authors discussed them amongst themselves. The resulting themes were refined to ensure consistency. Three experts conducted the analysis selection to determine the validity of the issues. The expert review phase ensured the clarity, importance, and suitability of each sub-theme by establishing domain validity.

Based on the overall reviews on the literature, the questions are as follow:

- i. What are the most promising retinal biomarkers for the early detection of Alzheimer's disease?
- ii. How do retinal structural changes correlate with cognitive impairment and neurodegeneration in Alzheimer's disease?
- iii. Can retinal biomarkers serve as non-invasive tools for early diagnosis and monitoring of Alzheimer's disease progression?
- iv. How effective is OCTA in identifying early biomarkers of Alzheimer's disease compared to other imaging techniques?
- v. What specific retinal vascular changes can OCTA detect that correlate with Alzheimer's disease progression?
- vi. Can OCTA be integrated into routine clinical practice for the early detection and differentiation of Alzheimer's disease subtypes?
- vii. How can machine learning models enhance the accuracy of Alzheimer's disease diagnosis using retinal imaging data?
- viii. What are the most effective machine learning algorithms for detecting early signs of Alzheimer's disease from retinal images?
- ix. How can computational approaches integrate multimodal retinal imaging data to improve the prediction of Alzheimer's disease progression?




Fig. 3. Flow diagram of the proposed searching study [26,27]

4. Results and Findings

This review was divided into three main themes which could be beneficial for future research. Details on each theme was discussed based on the 29 final data determined in the previous section.

4.1 Retinal and Ocular Biomarkers for Alzheimer's Disease

Recently, interest has shifted to the retinal and ocular biomarkers for the diagnosis of AD due to embryological similarity shared between the retina and the brain. Advanced imaging techniques, of which the most important ones are either OCT or OCTA, have further illuminated the way toward the identification of neurodegenerative changes associated with AD in the early stages of its development. Some studies did not find any correlation with macular vessel density in the superficial plexus regarding CSF biomarkers, while others found there to be significant reductions in macular microvascular density in AD patients that could be potential diagnostic biomarkers. The discrepancies here are such that the issue obviously requires further research. It has also been shown that there are prominent thinning of the retinal ganglion cell layer (GCL) and retinal nerve fibre layer (RNFL), correlating with reduced brain volumes, underscoring the potential utility of OCT for the early detection of neurodegenerative changes. A reduction in the levels of amyloid-beta in tears correlated with the retinal changes and brain changes related to AD, thus acting as a non-invasive biomarker for its early detection. Moreover, strong correlations in severe reductions of retinal thickness and vessel density with cognitive decline support the sensitivity of these measures for detecting AD. Comparative studies on retinal thinning patterns in AD and multiple sclerosis demonstrate a clear specificity. This is further confirmed by meta-analyses. The findings in this study of significant correlations between retinal microvasculature changes and grey matter volume in people at risk for AD during midlife prove that these changes are an early retinal indication of AD. Quantified capillaryfree zones show large zones as a major feature in high-risk individuals, which could work as novel biomarkers for the early detection of AD risks. These works together support the potential use of retinal imaging as a resourceful tool for unravelling AD neurodegeneration. Actually, these Avivements indicate that measurements of retinal biomarkers of AD, like macular VD, GCL, and RNFL thickness, provide optimum potential for non-invasive, presymptomatic diagnosis of AD, in addition to amyloid-β levels in tears. Such methods will only be successful if techniques further develop and requiring large, prospective cohort studies to create trustworthy diagnostic tools for AD.

Studies by Marquié *et al.*, [28,29] and García-Sánchez *et al.*, [30] evaluated the relationship of macular VD within the superficial plexus to CSF biomarkers of AD in subjects with aMCI and nondemented controls. These studies independently reached the same conclusion: no evidence was noted for a significant relationship between macular VD and CSF biomarkers, including A β 1-42, p181tau, and t-tau, and further, that brain vascular pathology and atrophy were found to be unrelated. These findings suggest that macular VD in the superficial plexus might not reflect early cerebrovascular impairment in the context of AD. Oppositely, Wang *et al.*, [31] recently present evidence for a significant decrease in macular microvascular density in a group of AD patients compared with matched controls. This decrease in macular microvascular density correlated with the cognitive impairment and APOE ϵ 4 genotypes, which suggested that the macular VD could be used as one diagnostic index for AD. These discrepancies may be because of varying designs, populations and stages of diseases associated with studies, thereby indicating further research into the topic is required to rectify these findings.

The study by López-de-Eguileta *et al.,* [32] and Mathew *et al.,* [33] focused on the retinal ganglion cell layer and retinal nerve fibre layer. López-de-Eguileta *et al.,* [32] found that in subjects free of

cognitive deficits but positive for CSF biomarkers of AD, such as tau proteins, there was significant thinning of the GCL and RNFL. The authors mentioned that this thinning went with a reduced hippocampal volume, and therefore, OCT may become useful in the description of early neurodegenerative changes before the appearance of cognitive symptoms. Similarly, Mathew *et al.*, evaluated the positive associations between RNFL thickness with brain volumes of areas such as the hippocampus and temporal lobe. These findings back clearly the potential utilities for RNFL measurements in monitoring brain neurodegeneration, which aids diagnosis of AD. Therefore, the correlational consistency of retinal layer thinning with a reduction in brain volume underpins these retinal biomarkers within the context of AD.

Gharbiya *et al.*, [34] investigated the potential diagnosis of AD using the levels of A β 1–42 in tears. According to the results, there is a strong correlation between the decrease in tear A^{β1}–42 and MCI and AD. At the same time, this decrease was strongly correlated with CT thinning and thus reflects that tear biomarkers could be helpful in supplying non-minimally invasive early detection of AD. These results are in agreement with a previous investigation by Hu et al., [35], which observed remarkable correlations between retinal changes and anatomic brain alterations in patients with the AD spectrum, thus providing further support for the application of non-invasive biomarkers in the early diagnosis of AD. AD patients, as opposed to Chaitanuwong et al., [36], exhibited substantial reductions in the thickness of the macula and vessel density at the level of the parafovea and perifovea compared with age-matched normal controls. These reductions correlated positively with cognitive decline, measured by Thai Mental State Examination scores. In this respect, it underlines the sensitivity of retinal thickness and VD in neurodegenerative changes associated with AD. Similarly, Hu et al., [35] observed correlations between the density of retinal vessels and hippocampal subfield volumes, as well as white matter tract integrity—retinal microvascular measures that may be early markers for structural brain changes related to AD. Garcia-Martin et al., [37] examined the differences in retinal thickness between AD and MS patients, showing different patterns of retinal thinning in these two conditions. This allows a priori differentiation from other neurodegenerative diseases finally resulting in dementia and underlines the specificity of the retinal changes associated with AD, which might be assessed by means of OCT. This specificity was further supported by Sheriff et al., [38], in a meta-analysis done to confirm the association of retinal thickness and vascular parameters with AD, to differentiate it from other neurological conditions.

The collective evidence underlines the potential of retinal imaging, particularly OCT and OCTA, to provide key insights into AD-related neurodegeneration. Some studies positioning the measurement of retinal changes as pertinent surrogates for AD biomarkers have established prominent associations, but others indicate a necessity for further replication across different populations and disease stages—which does not seem entirely improbable. The retinal biomarkers that currently show great promise for the non-invasive early diagnosis of AD are retinal vessel density, ganglion cell layer and RNFL thickness, and more sophisticated parameters such as the levels of amyloid-beta in tears. Further advances in imaging and larger prospective studies will be required to confirm the usefulness of these retinal parameters as diagnostic markers of AD.

Specifically, Rashid *et al.*, [39] investigated changes in retinal microvasculature within OCTA data for individuals from mid-life who are at risk of developing AD. According to the results, it was found that there were highly significant correlations between retinal vessel metrics and grey matter volume regions. These findings underline further the potential of changes to retinal microvasculature as early markers for AD and its asymptomatic stages. In a recent study, Arthur *et al.*, [40] have quantified the capillary-free zone at the periarteriole and perivenule in cognitively unimpaired older adults at high risk for AD. High-risk individuals had larger CFZs compared with low-risk controls, hence representing another potential novel retinal vascular biomarker for early risk detection of AD. Chimthanawala *et*

al., [41] performed a review regarding non-invasive biomarkers for the early detection of AD and underlined the role of techniques of retinal imaging. These biomarkers are detectable in various biological samples and show a positive correlation with brain pathology of AD, thus allowing an early diagnosis and management.

4.2 Optical Coherence Tomography Angiography (OCTA) and Imaging Techniques

The analysis was made related to OCTA and imaging techniques for several studies and summary on the findings are as tabulated in Table 3.

Summary of optical coherence tomography angiography and imaging techniques Author Objectives Findings **Conclusion & Future Research** Name and Year Chua J. Improve diagnostic Participants with MCI/AD showed Using interindividual variations in ocular et al., ability of OCT retinal significantly thinner measured anatomical features in cpRNFL [42] biomarkers to and compensated cpRNFL, mGCC, measurements and incorporating differentiate MCI/AD. and altered retinal vessel density. macular information may improve **Compensated RNFL** detection of person with early cognitive outperformed measured RNFL for impairment. Future research should discrimination of MCI/AD. explore further on these combinations. Sun Y. et OCTA may aid in non-invasive detection Investigate fundus PCA patients had thinner retinal al., [43] markers in PCA patients nerve fibre layer and ganglion cell of AD and PCA. Future research should substantiate these findings and improve 4and compare them layer + inner plexiform layer with typical AD patients compared to HC. diagnostic accuracy. to identify patterns. López-Analyse changes in Increased vascular density in OCTA shows promise as a biomarker for monitoring early vascular changes in AD. Cuenca I. retinal vascular network specific retinal sectors in et al., in subjects with high genetically at-risk subjects. Future research should validate these [44] genetic risk of Significant changes observed in biomarkers in larger cohorts and explore developing AD. participants with HCL and HBP. longitudinal changes. Wang L. Explore association Cognitive impairment group Retinal vascular structure characteristics et al., between cortical visual showed decreased functional could be used for diagnosing and [45] connectivity in the cortical visual monitoring AD progression. Future system and retinal vascular structures in AD system and deteriorated retinal research should refine these biomarkers vascular structure characteristics. and explore their clinical applicability. patients. Xie J. et **Develop OCTA analysis** Significant decrease in vessel OCTA provides useful biomarkers for al., [21] framework for early area, length densities, and clinical decision-making and diagnosis of detection of retinal number of bifurcations in AD and AD and MCI. Future research should microvascular changes standardize these tools and validate MCI groups. in AD and MCI. their use in clinical settings. Zhao B. Explore relationships of Decreased macular thickness Future studies should investigate OCTA et al., retinal differences with associated with cognitive in evaluating AD. More rigorous and [46] imaging in AD patients. function in mild AD patients. larger studies are needed. Rashid D. Investigate retinal Retinal vascular changes Future research should focus on relating et al., phenotypes in mid-life observed between control and findings into clinical practice for early AD [47] individuals at risk of at-risk groups. detection. Longitudinal study can be getting AD using OCTA. used to check changes over time. Liu S.Y. Develop a clinical-Polar-Net outperformed existing Polar-Net framework shows promise in methods, providing valuable et al., friendly DL model for AD AD detection. Future research should [48] detection in OCTA pathological evidence for retinal further validate this model and explore vascular changes related with AD. its integration into clinical workflows. images.

4.3 Machine Learning and Computational Approaches for Alzheimer's Disease Diagnosis

Implementation of machine learning and other computational approaches for diagnosis of AD were summarized in Table 4 in terms of objectives, methodologies implemented in the study, results as well as future research of the study.

Author	Objectives	and computational approa Methodologies		Results	Future research
Name and Year	objectives	IVIC		Nesures	i uture research
Yang H. <i>et</i> <i>al.</i> , [49]	Develop a distance-based novelty detection model to identify individuals at risk of developing AD.	1. 2. 3. 4.	Novelty Detection (ND) Mixture of Gaussian- based ND algorithm Distance to Boundary (DtB) strategy Web-based GUI	AUCs : 0.8757 and 0.9443, sensitivities : 96.79% and 89.09%, specificities : 89.63% and 90.92% for the AIBL and FMUUH datasets respectively.	Future research could enhance mode interpretability and integrate additional data sources.
Wisely C.E. <i>et al.,</i> [50]	Develop a convolutional neural network (CNN) to detect symptomatic AD using multimodal retinal imaging.	1. 2. 3. 4.	Convolutional Neural Network (CNN) Multimodal retinal images OCT and OCTA quantitative data Patient data.	UWF colour 0.450, OCTA SCP 0.582, UWF FAF 0.618, GC-IPL maps 0.809. Combined model AUC 0.836, images only model AUC 0.829, GC-IPL maps and data model AUC 0.841.	Future research may explore incorporating additional biomarkers and enhancing multimodal data integration.
Gao H. <i>et</i> al., [51]	Develop a dual- stream attention neural network to classify individuals with MCI based on multimodal retinal images.	1. 2. 3. 4. 5.	Dual-stream attention neural network Cross-modality fusion Variable scale dense residual model Multi-classifier Gradient-based Class Activation Mapping	High precision rates of 84.96% and 80.90% in classifying MCI and positive test scores for cognitive impairment, respectively.	Future research could refine the model and investigate additiona retinal biomarkers.
Irfanuddin C.M. <i>et</i> <i>al.,</i> [52]	Develop a deep learning approach to detect diseases using retinal images.	1. 2. 3.	Deep learning Retinal cross- sectional images Dataset of 21 MS patients & 14 healthy	Accuracy : 98.85% in classifying healthy and diseased individuals.	Future research should explore its application to other diseases and larger datasets.
Lustig- Barzelay Y. <i>et al.,</i> [53]	Assess the pupil light reflex (PLR) for early detection of AD in subjects with/without AD.	1. 2. 3.	Chromatic Pupilloperimetry Machine Learning (ML) Transient PLR for red and blue light stimuli	AUC-ROC of 0.90 (left-eye) and 0.87 (right-eye). Shorter PRL for dim blue light in high-risk group.	Future research could explore longitudinal studies and PLR parameters.
Mozdbar S. <i>et al.,</i> [54]	Examine the predictive ability of structural retinal biomarkers for detecting Cl in a primary care.	1. 2. 3. 4. 5.	OCT Visual acuity Ocular history questionnaire Eye pressure Fundus imaging	Top biomarkers included various quadrants of the retinal nerve fibre layer.	Future research should validate these findings in larger, diverse populations.

Table 4

Journal of Advanced Research in Applied Sciences and Engineering Technology Volume 61, Issue 2 (2026) 41-57

Vinoth Kumar M. <i>et al.,</i> [55]	Develop an enhanced LSTM model for early AD	1.	Enhanced Long Short- Term Memory (E- LSTM)	Improved prediction accuracy by 10% compared to existing systems.	Future research should use larger sample sizes and
	prediction using ocular biomarkers.	2.	Particle Swarm Optimization (PSO)		integrating additional ocular biomarkers.

5. Discussions and Conclusions

Research into the potential of retinal and ocular biomarkers for the diagnosis of Alzheimer's disease has been very promising, especially with the development of advanced imaging techniques such as optical coherence tomography and optical coherence tomography angiography. Some studies have shown associations between changes at the retina and AD biomarkers, which could be indicative of non-invasive early detection for AD. For these retinal measures to be considered as reliable diagnostic tools for AD, much more research and validation in different populations and at different stages of the disease are needed.

Several research studies have pointed out that OCT and OCTA could help not only in early diagnosis but also in differential diagnosis between AD and mild cognitive impairment. These studies assessed that there were significant differences in the retinal biomarkers—cpRNFL and mGCC thickness—between subjects with MCI and AD and those who are cognitively normal. These measurements are improved in terms of diagnostic accuracy by compensation for demographic and anatomical variations. Combining parameters for cpRNFL and mGCC achieves an improved AUC for the detection of MCI and AD, underscoring once more the additional value of multiple retinal layer parameters in assessments. Moreover, it enabled OCTA to detect distinct retinal changes in a subgroup of patients with dementia, namely PCA patients, showing its utility in differential diagnosis between the various forms of dementia. This is also reflected in the retinal vascular changes by genetic predispositions, like ApoE £4 status, positioning OCTA to monitor those at high risk for AD. Deep-learning-based models analysing OCTA images, such as Polar-Net, further facilitate the detection of retinal changes associated with AD in an Thu fashion, thus consistent with clinical observation, offering great promise for early diagnosis and monitoring of neurodegenerative diseases.

Specifically, owing to the use of advanced imaging and machine learning models, the detection of AD has become one of the prime areas of research aimed at providing an early and accurate diagnosis. Yang et al., present a distance-based novelty detection model on the AIBL and FMUUH cohorts that realizes high sensitivity and specificity, with a user-friendly GUI facilitating the detection of MCI and AD. Wisely et al., demonstrated that a CNN could actively identify AD with integrated multimodal retinal images and patient data; in that, GC-IPL maps were very useful. Gao et al., proposed a dual-stream attention neural network that applied multi-modal retinal images for positioning MCI with high precision, giving more importance to retinal biomarkers. Irfanuddin et al., propose an efficient deep learning approach that yields an accuracy of 98.85% for detecting neurodegenerative diseases from retinal scans and is cost-effective, hence accessible. Lustig-Barzelay et al., describe chromatic pupilloperimetry using machine learning for estimating AD-risk by minute changes in the light reflex of the pupils, hence offering a non-invasive early detection method. For instance, Mozdbar et al., studied the structural retinal biomarkers of cognitive impairment in a primary care setting and identified the main retinal layers that were relevant for prediction. Kumar et al., proposed E-LSTM with an optimization component of Particle Swarm Optimization to improve the accuracy of retinal image segmentation for AD prediction. These studies, when put together, prove the potential role for imaging the retina and machine learning in transforming the diagnosis of AD. However, additional research work should be done with more integration to get the best out of these approaches for their clinical applications.

Acknowledgement

This research was supported by Universiti Tun Hussein Onn Malaysia (UTHM) through Tier 1 (vot Q358).

References

- [1] Zhang, X-X., Y. Tian, Z-T. Wang, Y-H. Ma, Lan Tan, and Jin-Tai Yu. "The epidemiology of Alzheimer's disease modifiable risk factors and prevention." *The journal of prevention of Alzheimer's disease* 8 (2021): 313-321. <u>https://doi.org/10.14283/jpad.2021.15</u>
- [2] Porsteinsson, Anton P., R. S. Isaacson, Sean Knox, Marwan N. Sabbagh, and Ivana Rubino. "Diagnosis of early Alzheimer's disease: clinical practice in 2021." *The journal of prevention of Alzheimer's disease* 8 (2021): 371-386. https://doi.org/10.14283/jpad.2021.23
- [3] Tiwari, Sneham, Venkata Atluri, Ajeet Kaushik, Adriana Yndart, and Madhavan Nair. "Alzheimer's disease: pathogenesis, diagnostics, and therapeutics." *International journal of nanomedicine* (2019): 5541-5554. https://doi.org/10.2147/IJN.S200490
- [4] van Oostveen, Wieke M., and Elizabeth CM de Lange. "Imaging techniques in Alzheimer's disease: a review of applications in early diagnosis and longitudinal monitoring." *International journal of molecular sciences* 22, no. 4 (2021): 2110. <u>https://doi.org/10.3390/ijms22042110</u>
- [5] Chan, Victor TT, Zihan Sun, Shumin Tang, Li Jia Chen, Adrian Wong, Clement C. Tham, Tien Y. Wong *et al.*, "Spectraldomain OCT measurements in Alzheimer's disease: a systematic review and meta-analysis." *Ophthalmology* 126, no. 4 (2019): 497-510. <u>https://doi.org/10.1016/j.ophtha.2018.08.009</u>
- [6] Moussa, Mohamed, Yousra Falfoul, Amina Nasri, Khaled El Matri, Imen Kacem, Saloua Mrabet, Ahmed Chebil, Alya Gharbi, Riadh Gouider, and Leila El Matri. "Optical coherence tomography and angiography in Alzheimer's disease and other cognitive disorders." *European Journal of Ophthalmology* 33, no. 4 (2023): 1706-1717. https://doi.org/10.1177/11206721221148952
- [7] DeBuc, Delia Cabrera. "TD-P-10: Identification Of Retinal Biomarkers In Alzheimer's Disease Using Optical Coherence Tomography: Recent Insights, Challenges And Opportunities." *Alzheimer's & Dementia* 15 (2019): P156-P157. <u>https://doi.org/10.1016/j.jalz.2019.06.4321</u>
- [8] Mandangan, Arif, and Syahidatul Shafiqah Ramlee. "Chaotic Encryption Scheme for Double Grayscale Images using Sprott B Hyperchaotic Map." International Journal of Computational Thinking and Data Science 1, no. 1 (2024): 25-40. <u>https://doi.org/10.37934/CTDS.1.1.2540</u>
- [9] Khaw, L.W. & Abdullah, S.S. "MRI Brain Image Classification Using Convolutional Neural Networks And Transfer Learning." Journal of Advanced Research in Computing and Applications. 31, 1 (2024): 20–26. <u>https://doi.org/10.37934/arca.31.1.2026</u>
- [10] Shim, Chung Siong, Chia Yee Ooi, and Giap Seng Teoh. "Low Power Integrated Circuit Design of Extreme Learning Machine using Power Gating Methodology." *Journal of Advanced Research in Computing and Applications* 31: 13-19. <u>https://doi.org/10.37934/arca.31.1.1319</u>
- [11] Viedma, Ignacio A., David Alonso-Caneiro, Scott A. Read, and Michael J. Collins. "Deep learning in retinal optical coherence tomography (OCT): A comprehensive survey." *Neurocomputing* 507 (2022): 247-264. <u>https://doi.org/10.1016/j.neucom.2022.08.021</u>
- [12] Pekala, Mike, Neil Joshi, TY Alvin Liu, Neil M. Bressler, D. Cabrera DeBuc, and Philippe Burlina. "Deep learning based retinal OCT segmentation." *Computers in biology and medicine* 114 (2019): 103445. <u>https://doi.org/10.1016/j.compbiomed.2019.103445</u>
- [13] Akter, Nahida, John Fletcher, Stuart Perry, Matthew P. Simunovic, Nancy Briggs, and Maitreyee Roy. "Glaucoma diagnosis using multi-feature analysis and a deep learning technique." *Scientific Reports* 12, no. 1 (2022): 8064. <u>https://doi.org/10.1038/s41598-022-12147-y</u>
- [14]Sampath Kumar, Arunodhayan, Tobias Schlosser, Holger Langner, Marc Ritter, and Danny Kowerko. "Improving OCT
image segmentation of retinal layers by utilizing a machine learning based multistage system of stacked multiscale
encoders and decoders." *Bioengineering* 10, no. 10 (2023): 1177.
https://doi.org/10.3390/bioengineering10101177
- [15] Chen, Shuntai, Dian Zhang, Honggang Zheng, Tianyu Cao, Kun Xia, Mingwan Su, and Qinggang Meng. "The association between retina thinning and hippocampal atrophy in Alzheimer's disease and mild cognitive

impairment: a meta-analysis and systematic review." *Frontiers in Aging Neuroscience* 15 (2023): 1232941. https://doi.org/10.3389/fnagi.2023.1232941

- [16] Popovic, Natasa, Maša Ždralević, Stela Vujosevic, Miroslav Radunović, Antoaneta Adžić Zečević, Isidora Rovčanin Dragović, Batrić Vukčević *et al.*, "Retinal microvascular complexity as a putative biomarker of biological age: a pilot study." *Biogerontology* 24, no. 6 (2023): 971-985. <u>https://doi.org/10.1007/s10522-023-10057-8</u>
- [17] Adejumo, Tobiloba, Guangying Ma, Taeyoon Son, Tae-Hoon Kim, David Le, Albert K. Dadzie, Shaiban Ahmed, and Xincheng Yao. "Adaptive vessel tracing and segmentation in OCT enables the robust detection of wall-to-lumen ratio abnormalities in 5xFAD mice." *Biomedical Optics Express* 14, no. 12 (2023): 6350-6360. https://doi.org/10.1364/BOE.504317
- [18] Hui, Herbert YH, An Ran Ran, Jia Jia Dai, and Carol Y. Cheung. "Deep Reinforcement Learning-Based Retinal Imaging in Alzheimer's Disease: Potential and Perspectives." *Journal of Alzheimer's Disease* 94, no. 1 (2023): 39-50. <u>https://doi.org/10.3233/JAD-230055</u>
- [19] Batista, Ana, Pedro Guimarães, Pedro Serranho, Ana Nunes, João Martins, Paula I. Moreira, António Francisco Ambrósio, Miguel Morgado, Miguel Castelo-Branco, and Rui Bernardes. "Retinal imaging in animal models: Searching for biomarkers of neurodegeneration." *Frontiers in Ophthalmology* 3 (2023): 1156605. <u>https://doi.org/10.3389/fopht.2023.1156605</u>
- [20] Cordeiro, Maria Francesca, Daniel Hill, Radhika Patel, Paolo Corazza, John Maddison, and Saad Younis. "Detecting retinal cell stress and apoptosis with DARC: Progression from lab to clinic." *Progress in Retinal and Eye Research* 86 (2022): 100976. <u>https://doi.org/10.1016/j.preteyeres.2021.100976</u>
- [21] Sami, Nahid, Aaisha Makkar, Farid Meziane, and Myra Conway. "Exploring Imaging Biomarkers for Early Detection of Alzheimer's Disease Using Deep Learning: A Comprehensive Analysis." In International Conference on Recent Trends in Image Processing and Pattern Recognition, pp. 197-206. Cham: Springer Nature Switzerland, 2023. <u>https://doi.org/10.1007/978-3-031-53085-2_17</u>
- [22] Xie, Jianyang, Quanyong Yi, Yufei Wu, Yalin Zheng, Yonghuai Liu, Antonella Macerollo, Huazhu Fu et al., "Deep segmentation of OCTA for evaluation and association of changes of retinal microvasculature with Alzheimer's disease and mild cognitive impairment." British Journal of Ophthalmology 108, no. 3 (2024): 432-439. https://doi.org/10.1136/bjo-2022-321399
- [23] Prasath, T., and V. Sumathi. "Identification of Alzheimer's disease by imaging: a comprehensive review." International Journal of Environmental Research and Public Health 20, no. 2 (2023): 1273. <u>https://doi.org/10.3390/ijerph20021273</u>
- [24] Cheung, Carol Y., Vincent Mok, Paul J. Foster, Emanuele Trucco, Christopher Chen, and Tien Yin Wong. "Retinal imaging in Alzheimer's disease." *Journal of Neurology, Neurosurgery & Psychiatry* 92, no. 9 (2021): 983-994. <u>https://doi.org/10.1136/jnnp-2020-325347</u>
- [25] Jentsch, Susanne, Dietrich Schweitzer, Kai-Uwe Schmidtke, Sven Peters, Jens Dawczynski, Karl-Jürgen Bär, and Martin Hammer. "Retinal fluorescence lifetime imaging ophthalmoscopy measures depend on the severity of Alzheimer's disease." Acta ophthalmologica 93, no. 4 (2015): e241-e247. <u>https://doi.org/10.1111/aos.12609</u>
- [26] Moher, David, Alessandro Liberati, Jennifer Tetzlaff, Douglas G. Altman, and T. PRISMA Group*. "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement." *Annals of internal medicine* 151, no. 4 (2009): 264-269. <u>https://doi.org/10.7326/0003-4819-151-4-200908180-00135</u>
- [27] Mustafa, Wan Azani, Afiqah Halim, Mohd Wafi Nasrudin, and Khairul Shakir Ab Rahman. "Cervical cancer situation in Malaysia: A systematic literature review." *Biocell* 46, no. 2 (2022): 367. <u>https://doi.org/10.32604/biocell.2022.016814</u>
- [28] Marquié, Marta, Ainhoa García-Sánchez, Emilio Alarcón-Martín, Joan Martínez, Miguel Castilla-Martí, Luis Castilla-Martí, Adelina Orellana et al., "Macular vessel density in the superficial plexus is not associated to cerebrospinal fluid core biomarkers for Alzheimer's disease in individuals with mild cognitive impairment: The NORFACE cohort." Frontiers in Neuroscience 17 (2023): 1076177. https://doi.org/10.3389/fnins.2023.1076177
- [29] Marquié, Marta, Sergi Valero, Joan Martínez, Emilio Alarcón-Martín, Ainhoa García-Sánchez, Itziar de Rojas, Miguel Castilla-Martí et al., "Differences in macular vessel density in the superficial plexus across cognitive impairment: the NORFACE cohort." Scientific Reports 12, no. 1 (2022): 16938. <u>https://doi.org/10.1038/s41598-022-21558-w</u>
- [30] García-Sánchez, Ainhoa, Oscar Sotolongo-Grau, Juan Pablo Tartari, Ángela Sanabria, Ester Esteban-De Antonio, Alba Pérez-Cordón, Montserrat Alegret *et al.*, "Macular vessel density in the superficial plexus is not a proxy of cerebrovascular damage in non-demented individuals: data from the NORFACE cohort." *Alzheimer's Research & Therapy* 16, no. 1 (2024): 42.
- [31] Wang, Xin, Yaqin Wang, Hui Liu, Xiangyu Zhu, Xiaoli Hao, Yuan Zhu, Bei Xu *et al.*, "Macular microvascular density as a diagnostic biomarker for Alzheimer's disease." *Journal of Alzheimer's Disease* 90, no. 1 (2022): 139-149. <u>https://doi.org/10.3233/JAD-220482</u>

- [32] López-de-Eguileta, Alicia, Sara López-García, Carmen Lage, Ana Pozueta, María García-Martínez, Martha Kazimierczak, María Bravo et al., "The retinal ganglion cell layer reflects neurodegenerative changes in cognitively unimpaired individuals." Alzheimer's research & therapy 14, no. 1 (2022): 57. <u>https://doi.org/10.1186/s13195-022-00998-6</u>
- [33] Mathew, Sunu, Darrell WuDunn, Devin D. Mackay, Aaron Vosmeier, Eileen F. Tallman, Rachael Deardorff, Alon Harris et al., "Association of brain volume and retinal thickness in the early stages of Alzheimer's disease." *Journal* of Alzheimer's disease 91, no. 2 (2023): 743-752. <u>https://doi.org/10.3233/JAD-210533</u>
- [34] Gharbiya, Magda, Giacomo Visioli, Alessandro Trebbastoni, Giuseppe Maria Albanese, Mayra Colardo, Fabrizia D'Antonio, Marco Segatto, and Alessandro Lambiase. "Beta-amyloid peptide in tears: an early diagnostic marker of Alzheimer's disease correlated with choroidal thickness." *International Journal of Molecular Sciences* 24, no. 3 (2023): 2590. <u>https://doi.org/10.3390/ijms24032590</u>
- [35] Hu, Zheqi, Lianlian Wang, Dandan Zhu, Ruomeng Qin, Xiaoning Sheng, Zhihong Ke, Pengfei Shao, Hui Zhao, Yun Xu, and Feng Bai. "Retinal alterations as potential biomarkers of structural brain changes in Alzheimer's disease spectrum patients." *Brain Sciences* 13, no. 3 (2023): 460. <u>https://doi.org/10.3390/brainsci13030460</u>
- [36] Chaitanuwong, Pareena, Supharat Jariyakosol, Supanut Apinyawasisuk, Parima Hirunwiwatkul, Hathairat Lawanlattanagul, Solaphat Hemrungrojn, and Yuda Chongpison. "Changes in Ocular Biomarkers from Normal Cognitive Aging to Alzheimer's Disease: A Pilot Study." *Eye and Brain* (2023): 15-23. <u>https://doi.org/10.2147/EB.S391608</u>
- [37] Garcia-Martin, Elena, Daniel Jimeno-Huete, Francisco J. Dongil-Moreno, Luciano Boquete, Eva M. Sánchez-Morla, Juan M. Miguel-Jiménez, Almudena López-Dorado *et al.*, "Differential Study of Retinal Thicknesses in the Eyes of Alzheimer's Patients, Multiple Sclerosis Patients and Healthy Subjects." *Biomedicines* 11, no. 12 (2023): 3126. <u>https://doi.org/10.3390/biomedicines11123126</u>
- [38] Sheriff, Samran, Ting Shen, Sandra Abdal, Danit Saks, Mehdi Mirzaei, Veer Gupta, Nitin Chitranshi et al., "Retinal thickness and vascular parameters using optical coherence tomography in Alzheimer's disease: a metaanalysis." Neural Regeneration Research 18, no. 11 (2023): 2504-2513. <u>https://doi.org/10.4103/1673-5374.371380</u>
- [39] Rashid, Darwon, Ylenia Giarratano, Charlene Hamid, Tom MacGillivray, Graciela Muniz Terrera, Craig Ritchie, Baljean Dhillon *et al.*, "Associations Between Retinal Microvasculature Changes and Gray Matter Volume in a Mid-Life Cohort at Risk of Developing Alzheimer's Disease." In *International Workshop on Ophthalmic Medical Image Analysis*, pp. 1-10. Cham: Springer Nature Switzerland, 2023. <u>https://doi.org/10.1007/978-3-031-44013-7_1</u>
- [40] Arthur, Edmund, Swetha Ravichandran, Peter J. Snyder, Jessica Alber, Jennifer Strenger, Ava K. Bittner, Rima Khankan *et al.*, "Retinal mid-peripheral capillary free zones are enlarged in cognitively unimpaired older adults at high risk for Alzheimer's disease." *Alzheimer's Research & Therapy* 15, no. 1 (2023): 172. https://doi.org/10.1186/s13195-023-01312-8
- [41] Chimthanawala, Niyamat MA, Akash Haria, and Sadhana Sathaye. "Non-invasive biomarkers for early detection of Alzheimer's disease: a new-age perspective." *Molecular Neurobiology* 61, no. 1 (2024): 212-223. <u>https://doi.org/10.1007/s12035-023-03578-3</u>
- [42] Chua, Jacqueline, Chi Li, Lucius Kang Hua Ho, Damon Wong, Bingyao Tan, Xinwen Yao, Alfred Gan et al., "A multiregression framework to improve diagnostic ability of optical coherence tomography retinal biomarkers to discriminate mild cognitive impairment and Alzheimer's disease." *Alzheimer's Research & Therapy* 14, no. 1 (2022): 41. <u>https://doi.org/10.1186/s13195-022-00982-0</u>
- [43] Sun, Yan, Lumi Zhang, Hui Ye, Lumin Leng, Yi Chen, Yujie Su, Peifang Ren, Hong Lu, and Guoping Peng. "Potential ocular indicators to distinguish posterior cortical atrophy and typical Alzheimer's disease: a cross-section study using optical coherence tomography angiography." *Alzheimer's Research & Therapy* 16, no. 1 (2024): 64. https://doi.org/10.1186/s13195-024-01431-w
- [44] López-Cuenca, Inés, Alberto Nebreda, Alejandra García-Colomo, Elena Salobrar-García, Jaisalmer de Frutos-Lucas, Ricardo Bruña, Ana I. Ramírez *et al.*, "Early visual alterations in individuals at-risk of Alzheimer's disease: A multidisciplinary approach." *Alzheimer's Research & Therapy* 15, no. 1 (2023): 19. <u>https://doi.org/10.1186/s13195-023-01166-0</u>
- [45] Wang, Lianlian, Zheqi Hu, Haifeng Chen, Xiaoning Sheng, Ruomeng Qin, Pengfei Shao, Zhiyuan Yang et al., "Applying Retinal Vascular Structures Characteristics Coupling with Cortical Visual System in Alzheimer's Disease Spectrum Patients." Brain Sciences 13, no. 2 (2023): 339. <u>https://doi.org/10.3390/brainsci13020339</u>
- [46] Zhao, Bingying, Yibing Yan, Xingqi Wu, Zhi Geng, Yue Wu, Guixian Xiao, Lu Wang *et al.*, "The correlation of retinal neurodegeneration and brain degeneration in patients with Alzheimer's disease using optical coherence tomography angiography and MRI." *Frontiers in Aging Neuroscience* 15 (2023): 1089188. <u>https://doi.org/10.3389/fnagi.2023.1089188</u>
- [47] Rashid, Darwon, Ylenia Giarratano, Charlene Hamid, Tom MacGillivray, Graciela Muniz Terrera, Craig Ritchie, Baljean Dhillon, and Miguel O. Bernabeu. "Analysing Optical Coherence Tomography Angiography of Mid-Life

Persons at Risk of Developing Alzheimer's Disease Later in Life." In *International Workshop on Ophthalmic Medical Image Analysis*, pp. 12-21. Cham: Springer International Publishing, 2022. <u>https://doi.org/10.1007/978-3-031-16525-2_2</u>

- [48] Liu, Shouyue, Jinkui Hao, Yanwu Xu, Huazhu Fu, Xinyu Guo, Jiang Liu, Yalin Zheng, Yonghuai Liu, Jiong Zhang, and Yitian Zhao. "Polar-Net: A Clinical-Friendly Model for Alzheimer's Disease Detection in OCTA Images." In International Conference on Medical Image Computing and Computer-Assisted Intervention, pp. 607-617. Cham: Springer Nature Switzerland, 2023. <u>https://doi.org/10.1007/978-3-031-43990-2_57</u>
- [49] Yang, Hongqin, Jiangbing Mao, Qinyong Ye, Magda Bucholc, Shuo Liu, Wenzhao Gao, Jie Pan, Jiawei Xin, and Xuemei Ding. "Distance-based novelty detection model for identifying individuals at risk of developing Alzheimer's disease." Frontiers in Aging Neuroscience 16 (2024): 1285905. <u>https://doi.org/10.3389/fnagi.2024.1285905</u>
- [50] Wisely, C. Ellis, Dong Wang, Ricardo Henao, Dilraj S. Grewal, Atalie C. Thompson, Cason B. Robbins, Stephen P. Yoon et al., "Convolutional neural network to identify symptomatic Alzheimer's disease using multimodal retinal imaging." British Journal of Ophthalmology 106, no. 3 (2022): 388-395. <u>https://doi.org/10.1136/bjophthalmol-2020-317659</u>
- [51] Gao, Hebei, Shuaiye Zhao, Gu Zheng, Xinmin Wang, Runyi Zhao, Zhigeng Pan, Hong Li, Fan Lu, and Meixiao Shen. "Using a dual-stream attention neural network to characterize mild cognitive impairment based on retinal images." *Computers in Biology and Medicine* 166 (2023): 107411. https://doi.org/10.1016/j.compbiomed.2023.107411
- [52] Irfanuddin, Chowdhury Mohammad, Wasique Islam Shafin, Koushik Ahmed, Md Hasib Khan, Md Ashraful Alam, Rafeed Rahman, and Shakib Mahmud Dipto. "An efficient deep learning approach to detect neurodegenerative diseases using retinal images." In 2023 IEEE Asia-Pacific Conference on Computer Science and Data Engineering (CSDE), pp. 1-2. IEEE, 2023. <u>https://doi.org/10.1109/CSDE59766.2023.10487730</u>
- [53] Lustig-Barzelay, Yael, Ifat Sher, Inbal Sharvit-Ginon, Yael Feldman, Michael Mrejen, Shada Dallasheh, Abigail Livny et al., "Machine learning for comprehensive prediction of high risk for Alzheimer's disease based on chromatic pupilloperimetry." *Scientific Reports* 12, no. 1 (2022): 9945. <u>https://doi.org/10.1038/s41598-022-13999-0</u>
- [54] Mozdbar, Sima, Melissa Petersen, Fan Zhang, Leigh Johnson, Alex Tolman, Ramyashree Nyalakonda, Alejandra Gutierrez, and Sid O'Bryant. "Application of Structural Retinal Biomarkers to Detect Cognitive Impairment in a Primary Care Setting." Journal of Alzheimer's Disease Reports 6, no. 1 (2022): 749-755. <u>https://doi.org/10.3233/ADR-220070</u>
- [55] Vinoth Kumar, M., M. Prakash, M. Naresh Kumar, and H. Abdul Shabeer. "Enhanced Long Short Term Memory for Early Alzheimer's Disease Prediction." *Intelligent Automation & Soft Computing* 35, no. 2 (2023). <u>https://doi.org/10.32604/iasc.2023.025591</u>